期刊文献+

肺癌疫苗的临床研究现状 被引量:5

Present situation of Clinical Research in Lung Cancer Vaccine
下载PDF
导出
摘要 生物治疗是肺癌常规治疗模式的有益补充。肺癌的生物治疗主要包括两方面:免疫治疗和基因治疗,免疫治疗主要是通过各种手段提高机体对肿瘤主动或被动的免疫杀伤能力;基因治疗是通过对基因水平缺陷的修复或导入,强化某些抗肿瘤基因以达到治疗肿瘤的目的。肿瘤疫苗治疗属于肿瘤生物治疗的一种,具有安全性高、毒性反应小的特点。 Biotherapy is a useful supplement for the routine methods in treatment of lung cancer.Biotherapy has two main pathways,i.e.immunotherapy and genetherapy.Immunotherapy can improve the killing tumors ability actively or passively.Genetherapy can treat tumors by gene correction and antitumor gene enhancement.Tumor vaccine is one kind of biotherapy,which has high security and low toxicity.
作者 张燕 王哲海
出处 《医学综述》 2010年第22期3409-3413,共5页 Medical Recapitulate
关键词 肺肿瘤 生物疗法 免疫疗法 基因疗法 Lung cancer Biological therapy Immunotherapy Genetherapy
  • 相关文献

参考文献34

  • 1Nemunaitis J,Sterman D,Jablons D,et al.Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in nonsmall-cell lung cancer[J].Natl Cancer Ingt,2004,96(4):326-331. 被引量:1
  • 2Raez LE,Santos ES.Mudad R,et al.Clinical trials targeting lung cancer with act Ⅳ e immunotherapy:the scope of vaccines[J].Expert Rev Anticancer Ther,2005,5(4):635-644. 被引量:1
  • 3Kong F,Jirtle RL,Huang DH,et al.Plasma transforming growth factor-betal level before radiotherapy correlates with long term outcome of patients with lung carcinoma[J].Cancer,1999,86 (9):1712-1719. 被引量:1
  • 4Nemunaitis J,Dillman RO,Schwarzenberger PO,et al.Phase Ⅱ study of belagenpumatucel-L,a transforming growth factor-2 anti-sense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer[J].J Clin Oncol,2006,24(29):4721-4730. 被引量:1
  • 5Morris JC,Vahanian N,Janik JE.Phase Ⅰ study of an antitumor vaccination usinga(1,3)galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC)[J].J Clin Oncol,2005,23 (16S):2586. 被引量:1
  • 6Peat N,Gendler SJ,Lalani N,et al.Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice[J].Cancer Res,1992,52(7):1954-1960. 被引量:1
  • 7Rochlitz C,Figlin R,Squiban P,et al.Phase Ⅰ immunotherapy with a modified vaccinia virus(MVA)expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-posit Ⅳ e advanced cancer[J].Gene Med,2003,5(8):690-699. 被引量:1
  • 8Butts C,Murray N,Maksymiuk A,et al.Randomized phase Ⅱ B trial of BLP25 liposome vaccine in stage Ⅲ B and Ⅳ non-small cell lung cancer[J].J Clin Oncol,2006,23(27):6674-6681. 被引量:1
  • 9Sangha R,Butts C.L-BLP25:a peptide vaccine strategy in non small cell lung cancer.[J].Clin Cancer Res,2007,13(15 Pt 2):S4652-S4654. 被引量:1
  • 10Ramlau R,Quoix E,Rolski J,et al.A phase Ⅱ study of Tg4010 (Mva-Muc1-IL2)in association with chemotherapy in patients with stage Ⅲ/Ⅳ non-small cell lung cancer[J].Thorac Oncol,2008,3 (7):735-744. 被引量:1

同被引文献17

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部